denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: AstraZeneca, Genmab US, Inc. and Ipsen Biopharmaceuticals, Inc. Provided by Clinical Care Options, LLC in partnership with the Follicular Lymphoma Foundation.
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Combination therapy, Lymphomas, Non-Hodgkin lymphoma, Bispecific Antibody Therapy, B Cell lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Chemotherapy, Diseases, Indolent lymphoma, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Non-Biological therapies, Adverse Events
Hematology Disease Topics & Pathways:
Combination therapy, Lymphomas, Non-Hodgkin lymphoma, Bispecific Antibody Therapy, B Cell lymphoma, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Chemotherapy, Diseases, Indolent lymphoma, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Non-Biological therapies, Adverse Events
Friday, December 6, 2024: 11:00 AM-2:00 PM
Grand Hall C
(Manchester Grand Hyatt San Diego)
Chair:
Sonali M. Smith, MD, University of Chicago
Disclosures:
Smith: Regeneron: Other: Educational lecture; Genmab: Consultancy; Ono Pharmaceutical: Consultancy; Caris Life Sciences: Other: Spouse is employed by Caris Life Sciences.
Speakers:
Caron A. Jacobson, MD, MMSc, Dana-Farber Cancer Institute
and
Peter Martin, MD, Weill Cornell Medicine
Disclosures:
Jacobson: Instil Bio: Consultancy; Caribou Biosciences: Consultancy; ADC Therapeutics: Consultancy; Abintus Bio: Consultancy; Daiichi Sankyo: Consultancy; Bristol Myers Squibb/Celgene: Consultancy; ImmPACT Bio: Consultancy; Ipsen: Consultancy; Novartis: Consultancy; MorphoSys: Consultancy; Pfizer: Research Funding; AbbVie: Consultancy; Synthekine: Consultancy; Kite, a Gilead Company: Consultancy, Research Funding; Miltenyi: Consultancy. Martin: AbbVie, AstraZeneca, Beigene, Daiichi Sankyo, Genentech, Janssen, Merck, Pepromene: Consultancy.
Join CCO and The Follicular Lymphoma Foundation for an engaging symposium reviewing the latest advancements in relapsed/refractory (R/R) Follicular Lymphoma (FL) management. This dynamic event combines interactive case challenges, patient survey insights, and expert panel discussions, offering a comprehensive look at cutting-edge treatments and strategies. Engage directly with leading experts through multiple Q&A sessions, where you can present your questions and real-world cases for personalized guidance. Navigate the evolving landscape of R/R FL treatment, explore the implementation of the newest therapies, and gain insights into future strategies heading into 2025. This symposium promises to enrich your understanding of R/R FL, challenge your clinical acumen, and empower you to apply the latest knowledge in your practice. Contribute to thought-provoking dialogues on R/R FL, shaping the discourse and enhancing collective expertise in this critical field.
See more of: Friday Satellite Symposia